Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 776-783

  Sale, Matthew J ^a   Cook, Simon J ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Acquired resistance; BRAF; Extracellular signal regulated kinase 1 2 (ERK1 2); Intrinsic resistance; Mitogen activated protein kinase (MAPK) extracellular signal regulated kinase (ERK) kinase 1 2 (MEK1 2); RAS

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE INHIBITOR; COBIMETINIB; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2 INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVITOCLAX; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

ANTIPROLIFERATIVE ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONFERENCE PAPER; DRUG RESISTANCE; GENE OVEREXPRESSION; HCT116 CELL LINE; HUMAN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; METASTATIC MELANOMA; NEGATIVE FEEDBACK; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS;

EID: 84905819939     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140129     Document Type: Conference Paper

References (54)

1. Ramos, J.W. (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol. 40, 2707-2719
2. Meloche, S. and Pouysségur, J. (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239
3. Balmanno, K. and Cook, S.J. (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16, 368-377
4. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., Ludlam, M.J., Stokoe, D., Gloor, S.L., Vigers, G. et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435
5. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C. and Marais, R. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221
6. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. and Rosen, N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430
7. Anforth, R.M., Blumetti, T.C., Kefford, R.F., Sharma, R., Scolyer, R.A., Kossard, S., Long, G.V. and Fernandez-Peñas, P. (2012) Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167, 1153-1160
8. Callahan, M.K., Rampal, R., Harding, J.J., Klimek, V.M., Chung, Y.R., Merghoub, T., Wolchok, J.D., Solit, D.B., Rosen, N., Abdel-Wahab, O. et al. (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321
9. Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J.S., Kong, X., Koya, R.C., Flaherty, K.T. et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215
10. Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F. et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632
11. Yeh, T.C., Marsh, V., Bernat, B.A., Ballard, J., Colwell, H., Evans, R.J., Parry, J., Smith, D., Brandhuber, B.J., Gross, S. et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583
12. Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362
13. Balmanno, K., Chell, S.D., Gillings, A.S., Hayat, S. and Cook, S.J. (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 125, 2332-2341
14. Delaney, A.M., Printen, J.A., Chen, H., Fauman, E.B. and Dudley, D.T. (2002) Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol. 22, 7593-7602
15. Friday, B.B., Yu, C., Dy, G.K., Smith, P.D., Wang, L., Thibodeau, S.N. and Adjei, A.A. (2008) BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 6145-6153
16. Hatzivassiliou, G., Haling, J.R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J.F., Zak, M., Peck, A., Orr, C. et al. (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501, 232-236
17. Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K. et al. (2014) Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697-710
18. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B. and Rosen, N. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. U.S.A. 106, 4519-4524
19. Lito, P., Pratilas, C.A., Joseph, E.W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W.L., Callahan, M.K., Merghoub, T. et al. (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682
20. Gilmartin, A.G., Bleam, M.R., Groy, A., Moss, K.G., Minthorn, E.A., Kulkarni, S.G., Rominger, C.M., Erskine, S., Fisher, K.E., Yang, J. et al. (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000
21. Ishii, N., Harada, N., Joseph, E.W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H. et al. (2013) Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060
22. Ohren, J.F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197
23. Sheth, P.R., Liu, Y., Hesson, T., Zhao, J., Vilenchik, L., Liu, Y.H., Mayhood, T.W. and Le, H.V. (2011) Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. Biochemistry 50, 7964-7976
24. Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J.D., Chresta, C.M., Smith, P.D., Fang, B. and Roth, J.A. (2009) High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol. Ther. 8, 2073-2080
25. Wee, S., Jagani, Z., Xiang, K.X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W.R., Lengauer, C. and Stegmeier, F. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286-4293
26. Paraiso, K.H., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., Munko, A.C., Wood, E., Fedorenko, I.V., Sondak, V.K., Anderson, A.R. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760
27. Smalley, K.S., Lioni, M., Dalla Palma, M., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A.J., Van Belle, P. et al. (2008) Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883
28. Haq, R., Yokoyama, S., Hawryluk, E.B., Jönsson, G.B., Frederick, D.T., McHenry, K., Porter, D., Tran, T.N., Love, K.T., Langer, R. et al. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 110, 4321-4326
29. Mirzoeva, O.K, Collisson, E.A., Schaefer, P.M., Hann, B., Hom, Y.K., Ko, A.H. and Korn, W.M. (2013) Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol. Cancer Ther. 12, 2213-2225
30. Troiani, T., Vecchione, L., Martinelli, E., Capasso, A., Costantino, S., Ciuffreda, L.P., Morgillo, F., Vitagliano, D., D'Aiuto, E., De Palma, R. et al. (2012) Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br. J. Cancer 106, 1648-1659
31. Tentler, J.J., Nallapareddy, S., Tan, A.C., Spreafico, A., Pitts, T.M., Morelli, M.P., Selby, H.M., Kachaeva, M.I., Flanigan, S.A., Kulikowski, G.N. et al. (2010) Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol. Cancer Ther. 9, 3351-3362
32. Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W.G., Ji, L., Minna, J.D., Fang, B. and Roth, J.A. (2011) STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 71, 3658-3668
33. Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J.M., Knauf, J.A., Viale, A., Sherman, E.J., Ryder, M., Ghossein, R.A., Rosen, N. and Fagin, J.A. (2013) Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520-533
34. Basile, K.J., Abel, E.V. and Aplin, A.E. (2012) Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471-2479
35. Abel, E.V., Basile, K.J., Kugel, C.H., Witkiewicz, A.K., Le, K., Amaravadi, R.K., Karakousis, G.C., Xu, X., Xu, W., Schuchter, L.M. et al. (2013) Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168
36. Corcoran, R.B., Rothenberg, S.M., Hata, A.N., Faber, A.C., Piris, A., Nazarian, R.M., Brown, R.D., Godfrey, J.T., Winokur, D., Walsh, J. et al. (2013) TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, ra98
37. Mahon, F.X., Deininger, M.W.N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M. and Melo, J.V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079
38. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. and Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
39. Emery, C.M., Vijayendran, K.G., Zipser, M.C., Sawyer, A.M., Niu, L., Kim, J.J., Hatton, C., Chopra, R., Oberholzer, P.A., Karpova, M.B. et al. (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 20411-20416
40. Villanueva, J., Infante, J.R., Krepler, C., Reyes-Uribe, P., Samanta, M., Chen, H.Y., Li, B., Swoboda, R.K., Wilson, M., Vultur, A. et al. (2013) Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4, 1090-1099
41. Corcoran, R.B., Dias-Santagata, D., Bergethon, K., Iafrate, A.J., Settleman, J. and Engelman, J.A. (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84
42. Little, A.S., Balmanno, K., Sale, M.J., Newman, S., Dry, J.R., Hampson, M., Edwards, P.A., Smith, P.D. and Cook, S.J. (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4, ra17
43. Wang, H., Daouti, S., Li, W.H., Wen, Y., Rizzo, C., Higgins, B., Packman, K., Rosen, N., Boylan, J.F., Heimbrook, D. and Niu, H. (2011) Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res. 71, 5535-5545
44. Morris, E.J., Jha, S., Restaino, C.R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S. et al. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750
45. Modrek, B., Ge, L., Pandita, A., Lin, E., Mohan, S., Yue, P., Guerrero, S., Lin, W.M., Pham, T., Modrusan, Z. et al. (2009) Oncogenic activating mutations are associated with local copy gain. Mol. Cancer Res. 7, 1244-1252
46. Soh, J., Okumura, N., Lockwood, W.W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D.S., Tang, X., MacAulay, C. et al. (2009) Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 4, e7464
47. Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J.M., Hoeflich, K.P., Haverty, P.M., Soriano, R., Forrest, W.F., Heldens, S., Chen, H. et al. (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11, 1143-1154
48. Little, A.S., Smith, P.D. and Cook, S.J. (2013) Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 32, 1207-1215
49. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G. et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599
50. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N. et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703
51. Wagle, N., Van Allen, E.M., Treacy, D.J., Frederick, D.T., Cooper, Z.A., Taylor-Weiner, A., Rosenberg, M., Goetz, E.M., Sullivan, R.J., Farlow, D.N. et al. (2014) MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68
52. Sale, M.J. and Cook, S.J. (2013a) That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br. J. Pharmacol. 169, 1708-1722
53. Sale, M.J. and Cook, S.J. (2013b) The BH3-mimetic ABT-263 synergises with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem. J. 450, 285-294
54. Corcoran, R.B., Cheng, K.A., Hata, A.N., Faber, A.C., Ebi, H., Coffee, E.M., Greninger, P., Brown, R.D., Godfrey, J.T., Cohoon, T.J. et al. (2013) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23, 121-128